Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status
Executive Summary
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.
You may also be interested in...
Teva Edges Closer To Growth, But With A Big Overhang
Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.
Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Lundbeck Set For 'Transformative' Eptinezumab Launch
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.
Need a specific report? 1000+ reports available
Buy Reports
